# OnCo record cd19-expression (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/cd19-expression/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "cd19-expression" ;
  schema:name "CD19 expression (CD19-positive)"@en ;
  schema:alternateName "CD19-positive"@en, "CD19+"@en, "CD19 expression"@en, "CD19 positive B-ALL"@en, "CD19 loss"@en, "CD19-negative relapse"@en ;
  schema:description "CD19 is the B-cell surface protein that blinatumomab, CAR-T cells and several antibodies aim at. Blinatumomab's label requires CD19-positive leukaemia; the CAR-T labels assume it, and losing CD19 is the commonest way the disease escapes."@en ;
  schema:url <https://onco.cc/biomarkers/cd19-expression/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38b482a8-960b-4591-9857-5031ecb830aa> ;
  onco:tag "biomarker", "surface-antigen" ;
  onco:related <https://onco.cc/biomarkers/cd22-expression/>, <https://onco.cc/biomarkers/cd20-expression/> ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-relapsed/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/zynlonta/> ;
  onco:terms <https://onco.cc/terms/flow-cytometry/>, <https://onco.cc/terms/antigen-escape/>, <https://onco.cc/terms/mrd/> .